Compare TTEC & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTEC | UNCY |
|---|---|---|
| Founded | 1982 | 2016 |
| Country | United States | United States |
| Employees | 69400 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.5M | 145.3M |
| IPO Year | 1996 | 2021 |
| Metric | TTEC | UNCY |
|---|---|---|
| Price | $2.36 | $7.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 455.3K | ★ 765.0K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.80 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,509,171,000.00 | $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.10 | $582.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.15 | N/A |
| 52 Week Low | $1.98 | $3.72 |
| 52 Week High | $5.59 | $8.74 |
| Indicator | TTEC | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 49.14 |
| Support Level | $2.12 | $6.81 |
| Resistance Level | $2.74 | $7.43 |
| Average True Range (ATR) | 0.17 | 0.58 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 38.89 | 41.43 |
TTEC Holdings Inc provides customer engagement management tools and services. The company operates through two operating segment, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and its revenues are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.